Fabio Chianelli

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU) for the development and commercialization of the IP of ketamine for the treatment of the Rett Syndrome (RTS), a rare genetic...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders announced that the US States Patent and Trademark Office (“USPTO”) granted US Patent...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.  The company, which focuses on delivering ketamine for treating mental health disorders  closed the annual period as follows:  Cash...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at the MDS International Congress of...

PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs.  KETARX consists of hydrogel-forming...

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for its “Compositions and Methods for Treating Motor Disorders” patent, intended to cover potential ketamine treatment of...

The Week In Psychedelics Atai Launches ‘Precision Psychiatry’ Subsidiary The Psychedelics Sector Reaches 50 Public Companies Listed In The U.S. Pasithea Therapeutics To Launch Its First Ketamine Clinic In The UK PharmaTher Receives FDA Orphan Drug Designation For Ketamine...